Dr. Hemal Gada: Evolut TAVR Demonstrates 'Favorable' Clinical Outcomes

Recent data on more than 150 patients from the Optimize PRO FX addendum study were released and presented by Dr. Hemal Gada, president of the UPMC Heart and Vascular Institute and medical director of the Structural Heart Program at UPMC.

DocWire News spoke with Dr. Gada about this study, which assessed valve performance and procedural outcomes in patients who underwent transcatheter aortic valve replacement (TAVR) with the Evolut FX TAVR system. The evidence “reveals favorable clinical and hemodynamic outcomes with Evolut TAVR,” Dr. Gada noted.